Cubist Systematic Strategies’s Autolus Therapeutics AUTL Stock Holding History

Cubist Systematic Strategies’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$260K	Buy	159,408 +51,650	+48%	+$101K	﹤0.01%	2569
2025 Q2	$246K	Buy	+107,758	New	+$178K	﹤0.01%	2528
2024 Q2	–	Sell	-160	Closed	-$1.02K	–	2972
2024 Q1	$1.02K	Sell	160 -31,809	-99%	-$198K	﹤0.01%	3598
2023 Q4	$206K	Buy	+31,969	New	+$122K	﹤0.01%	2987
2023 Q2	–	Sell	-133,860	Closed	-$246K	–	3490
2023 Q1	$246K	Buy	133,860 +121,373	+972%	+$237K	﹤0.01%	3107
2022 Q4	$23.7K	Sell	12,487 -131	-1%	-$331	﹤0.01%	3980
2022 Q3	$27K	Sell	12,618 -8,869	-41%	-$26.3K	﹤0.01%	4204
2022 Q2	$61K	Buy	+21,487	New	+$65.4K	﹤0.01%	4063
2022 Q1	–	Sell	-26,854	Closed	-$139K	–	3550
2021 Q4	$139K	Buy	+26,854	New	+$161K	﹤0.01%	3126
2021 Q3	–	Sell	-20,244	Closed	-$134K	–	2956
2021 Q2	$134K	Sell	20,244 -5,730	-22%	-$35.6K	﹤0.01%	2672
2021 Q1	$149K	Buy	+25,974	New	+$192K	﹤0.01%	2558
2020 Q2	–	Sell	-245	Closed	-$1K	–	2389
2020 Q1	$1K	Buy	245 +160	+188%	+$1.48K	﹤0.01%	2119
2019 Q4	$1K	Buy	+85	New	+$1.11K	﹤0.01%	2387

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cubist Systematic Strategies's AUTL Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Autolus Therapeutics (AUTL) stake by 48% in Q3 2025, buying an estimated $101K and bringing the position to 159,408 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #2569.

Cubist Systematic Strategies first reported a position in AUTL in Q4 2019 and has held it in 13 quarters since. 96 funds tracked by Wall St. Rank hold AUTL as of Q3 2025.

Cubist Systematic Strategies held 159,408 shares of Autolus Therapeutics worth $260K as of Q3 2025.
Cubist Systematic Strategies bought 51,650 Autolus Therapeutics shares in Q3 2025, an estimated $101K.
Autolus Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2569 holding.
Cubist Systematic Strategies first reported a position in Autolus Therapeutics in Q4 2019 and has held it in 13 quarters since.
96 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.